July 2026 in “Current Issues in Molecular Biology” This study found that Plerixafor, a CXCR4 antagonist, promotes melanogenesis in melanocytes by increasing MITF and tyrosinase expression and enhancing melanocyte migration, and it effectively restores pigmentation in a mouse depigmentation model without toxicity, highlighting its potential for treating pigmentary disorders.
March 2026 in “Preprints.org” In this study, plerixafor was found to enhance melanogenesis and promote repigmentation by engaging a β-arrestin–β-catenin–MITF signaling axis in melanocytes, and showed effectiveness in restoring depigmentation in a murine model without causing systemic toxicity.
49 citations
,
March 2014 in “Journal of Investigative Dermatology” This study demonstrated that combining AMD3100 with low-dose tacrolimus in a stem cell mobilization approach significantly reduced wound healing time and improved scar and hair follicle regeneration in full-thickness skin wounds.
This study found that combining AMD3100 and low-dose FK506 significantly improved and accelerated the healing of diabetic wounds in rats, suggesting a promising therapeutic approach for wound care in diabetes.